Roche announced that the European Commission (EC) has given its approval for the significantly wider use of its anti-angiogenic agent Avastin (bevacizumab) in patients suffering from metastatic colorectal cancer. This new broader label will now allow Avastin to be used in combination with any chemotherapy, including Roche’s oral chemotherapy Xeloda (capecitabine)*, for 1st and later treatment lines in patients with metastatic colorectal cancer.

More: continued here

This entry was posted on Tuesday, January 29th, 2008 at 7:01 pm and is filed under Cancer. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.